RSV Vaccine Shows Hopeful Early Results In 50 To 59-Year-Olds, GSK Says
GSK said they plan to submit data to regulators as soon as possible and expect a decision in 2024 on whether the shot, already approved for older adults, can be marketed towards people ages 50 to 59.
GSK said they plan to submit data to regulators as soon as possible and expect a decision in 2024 on whether the shot, already approved for older adults, can be marketed towards people ages 50 to 59.
What's Your Reaction?
